RxDoctor Payments Data

Natalie Dishman, MD

Internal Medicine · Morgan City, LANPI 1225036833

Payments from drug & device makers

$16,798in general payments, 2019–2025

Across 1,013 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • GSK$1K
  • Pfizer$992
  • AstraZeneca$986
  • Lilly USA, LLC$762
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$16,53298%
  • Education$2662%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)153$2,239
Novo Nordisk83$1,577
GSK88$1,294
Pfizer75$992
AstraZeneca48$986
Lilly USA, LLC52$762
Astellas Pharma US Inc31$701
Johnson & Johnson40$641
Amgen27$535
Merck34$512
Boehringer Ingelheim35$500
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)25$459
Takeda Pharmaceuticals U.S.A., Inc.27$452
Bayer18$416
Sanofi-aventis U.S. LLC25$380
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC30$365
Teva Pharmaceuticals USA, Inc.17$305
Ironwood Pharmaceuticals, Inc20$280
Axsome Therapeutics, Inc.9$277
Amarin Pharma, Inc.15$258
Abbott14$252
Otsuka America Pharmaceutical, Inc.10$204
Mylan Specialty L.p.11$200
Corium, LLC15$191
Eisai Inc.9$176
Novartis11$154
Lundbeck LLC5$135
Sumitomo Pharma America, Inc.6$119
Biogen8$119
Tolmar, Inc.6$102
Dexcom, Inc.5$98
Phathom Pharmaceuticals, Inc.7$91
Daiichi Sankyo Inc.4$86
Arbor Pharmaceuticals, Inc.5$81
Jazz Pharmaceuticals Inc.3$72
Biohaven Pharmaceutical Holding Company Ltd.3$54
Esperion Therapeutics, Inc.3$52
Urovant Sciences Inc3$51
Exact Sciences3$50
Ardelyx, Inc.2$42
Inspire Medical Systems, Inc.1$42
Verona Pharma, Inc.2$41
Smith+Nephew2$41
Seqirus USA Inc2$37
Xeris Pharmaceuticals, Inc.2$36
Biohaven Pharmaceuticals, Inc.2$34
Neurocrine Biosciences, Inc.2$33
Sanofi Pasteur Inc.2$28
Halozyme Inc1$24
Antares Pharma, Inc.1$23
Vapotherm Inc1$21
Kowa Pharmaceuticals America, Inc.1$21
Alnylam Pharmaceuticals Inc.1$21
Hikma Pharmaceuticals USA1$18
E.r. Squibb & Sons, L.L.C.1$18
Shire North American Group Inc1$18
Boston Scientific1$17
Gilead1$17
Azurity Pharmaceuticals, Inc.1$16
Supernus Pharmaceuticals, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,798 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$197,354
Medicare patients
558
Services billed
9,877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide217$234,285
EliquisApixaban528$211,390
JanuviaSitagliptin Phosphate225$144,695
MounjaroTirzepatide129$143,197
JardianceEmpagliflozin167$141,050
FarxigaDapagliflozin Propanediol233$121,099
VraylarCariprazine Hcl87$108,185
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$83,732
LinzessLinaclotide111$76,090
Soliqua 100-33Insulin Glargine/Lixisenatide54$57,835
XareltoRivaroxaban110$55,723
MyrbetriqMirabegron139$55,164
RybelsusSemaglutide43$48,152
TradjentaLinagliptin78$44,665
TrulicityDulaglutide42$42,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,577$282,437260 claims
AbbVieVraylar, Linzess, Qulipta, Ubrelvy$2,239$235,302234 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$500$211,549286 claims
PfizerEliquis$992$211,390528 claims
Lilly USA, LLCMounjaro, Trulicity$762$185,629171 claims
MerckJanuvia$512$144,695225 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,294$139,011220 claims
AstraZenecaFarxiga, Symbicort$986$130,411272 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$380$57,83554 claims
Johnson & JohnsonXarelto$641$55,723110 claims
Astellas Pharma US IncMyrbetriq$701$55,164139 claims
AmgenOtezla$535$33,45214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Morgan City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →